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CN1
LONG-TERm ImPACT Of THE dUTCH COLORECTAL CANCER SCREENING 
PROGRAmmE ON CANCER INCIdENCE: ExPLORATION Of THE SERRATEd 
PATHwAy
Greuter M.J.1, Lew J.B.2, Berkhof J.1, Canfell K.2, Dekker E.3, Meijer G.A.1, Coupe V.M.1
1VU University Medical Center, Amsterdam, The Netherlands, 2University of New South Wales, 
Sydney, Australia, 3Academic Medical Center, Amsterdam, The Netherlands
Objectives: The Netherlands has recently started with the stepwise implemen-
tation of biennial faecal immunochemical testing for colorectal cancer (CRC). We 
evaluated the impact of the transition to, and the fully implemented screening pro-
gramme on the long-term CRC incidence and colonoscopy demand. MethOds: The 
previously reported and calibrated ASCCA model was set up to simulate the Dutch 
CRC screening programme between 2014 and 2044. We adopted an open-model 
approach by simulating multiple birth cohorts and combining the results while 
accounting for the ageing of the population. Besides a no screening scenario, we 
evaluated the impact of screening under three sets of natural history assumptions 
which differed in the contribution of the serrated pathway to the CRC incidence 
(0%, 15% and 30%). Model-predicted outcomes were CRC incidence and colonoscopy 
demand per year. Results: Due to ageing, the model-predicted CRC incidence in 
the no screening scenario increased from 77/100,000 in 2014 to 109/100,000 in 2044. 
Under screening, the predicted CRC incidence in 2014 was between 105/100,000 
(assuming all CRCs originate from adenomas) and 109/100,000 (assuming that 30% of 
CRCs arises from serrated lesions) due to the detection of asymptomatic, prevalent 
tumours. After this peak, the predicted incidence gradually decreased until in 2039 a 
new equilibrium was reached, ranging between 65/100,000 and 71/100,000 assuming 
that 100% versus 70% of CRCs originate from adenomas, respectively. Due to the 
stepwise implementation, the predicted number of colonoscopies required for the 
screening programme increased gradually over time from 38,000 (752,199 invitees) 
in 2014 to 117,000 (2,154,875 invitees) in 2044. cOnclusiOns: The Dutch screening 
programme will markedly decrease CRC incidence in the next 25 years. The conclu-
sions about the impact of screening were robust to key natural history assumptions. 
With the results of this study, decision-makers can anticipate the expected change 
in CRC-related health care use and colonoscopy demand.
CN2
PRImARy TREATmENTS fOR INTERmEdIATE-RISk PROSTATE CANCER: A COST-
EffECTIvENESS ANd vALUE-Of-INfORmATION ANALySIS
Piena M.1, IJzerman M.J.2, Steuten L.M.G.3
1PANAXEA bv, Enschede, The Netherlands, 2University of Twente and MIRA institute for 
Biomedical Technology & Technical Medicine, Enschede, The Netherlands, 3University of Twente, 
Enschede, The Netherlands
Objectives: Intermediate-risk prostate cancer patients are recommended pri-
mary treatment with either radical prostatectomy (RP), external beam radio-
therapy (EBRT), brachytherapy (BT), or EBRT plus high-dose rate BT boost (EBRT 
+ HDR-BT); or expectant management with active surveillance (AS). The costs 
of these treatments differ considerably, whilst the amount and quality of evi-
dence for their comparative effectiveness in terms of disease progression, 
adverse events and health-related quality of life is unbalanced and inconclusive. 
Therefore, we undertook a cost-effectiveness analysis of RP, EBRT, BT, EBRT + 
HDR-BT and AS, and performed a value-of-information analysis to direct future 
research. MethOds: We developed a probabilistic Markov model estimating the 
expected incremental cost/(Quality Adjusted) Life Years from a UK-NHS perspec-
tive, with a time horizon of 10 years. Input data were obtained from the best 
available literature. We explored the uncertainty around the model outcomes by 
identifying the most influential parameters and estimating the expected value 
of perfect (parameter) information. Results: AS is most likely to be cost-effec-
tive at a cost/QALY threshold (λ ) < ₤3,000/QALY, BT for λ ₤3,000 to ₤12,000/QALY 
and RP for λ > ₤12,000/QALY. One-way sensitivity analysis shows that utilities 
and probabilities of adverse events are main effect drivers and initial treatment 
costs are main cost drivers. Large decision uncertainty exists around λ ₤11,000 
with a population EVPI of nearly ₤100 million. The EVPPI suggests that eliminat-
ing uncertainty around costs and utilities is most worthwhile. cOnclusiOns: 
With current information AS and BT are cost-effective treatments for 
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intermediate-risk prostate cancer at relatively low cost/QALY thresholds, 
and RP is expected to be the most cost-effective of available treatments at the 
prevailing range of cost/QALY thresholds (i.e. ₤20,000-₤30,000) . However, large 
decision uncertainty exists and acquiring further information is likely cost-effec-
tive. Future research on costs and utilities associated with treatment outcome and 
adverse events is expected to be most valuable.
CN3
EARLy STAGE COST-EffECTIvENESS ANALySIS Of A BRCA1-LIkE TEST TO 
dETECT TRIPLE NEGATIvE BREAST CANCERS RESPONSIvE TO HIGH dOSE 
ALkyLATING CHEmOTHERAPy
Miquel Cases A.1, Steuten L.M.G.2, Retèl V.P.1, van Harten W.H.2
1Netherlands Cancer Institute, Amsterdam, The Netherlands, 2University of Twente, Enschede, The 
Netherlands
Objectives: Triple negative breast cancers (TNBC) with a BRCA1-like profile may 
benefit from high dose alkylating chemotherapy (HDAC). This study examines 
whether treating TNBC with personalized HDAC based on BRCA1-like testing can 
be more cost-effective than current clinical practice. Additionally we estimated 
the minimum required prevalence of BRCA1-likeness and the required positive 
predictive value (PPV) for a BRCA1-like test to render this strategy cost-effec-
tive. MethOds: Our markov model compared the outcomes of treating TNBC 
women with personalized HDAC based on BRCA1-like testing vs. current clinical 
practice from a societal Dutch perspective and a 20-year time horizon. From our 
base-case model we assessed: 1) the incremental number of respondents; 2) the 
incremental number of Quality Adjusted Life Years, 3) the incremental costs, and 
4) the incremental cost-effectiveness ratio (ICER). We performed one-way sensi-
tivity analysis (SA) of all model parameters, and two-way SA of prevalence and 
PPV. Data were obtained from a current trial (NCT01057069), published literature 
and expert opinions where necessary. Results: Based on our base-case analysis 
with 68% BRCA1-like prevalence, 100% PPV, and costs of € 164 / test, treating TNBC 
according to BRCA1-like testing would be cost-effective (€ 16.192/QALY). One-way 
SA on the prevalence and PPV demonstrated that only the PPV drives the ICER 
changes. In two-way SA, the lower bound for the two parameters was: prevalence 
39.6% and PPV 46.4%. Regardless of prevalence, at PPVs > 46.4% BRCA1-like testing 
was always cost-effective. cOnclusiOns: Treating TNBC with personalized HDAC 
based on BRCA1-like testing is expected to be cost-effective at a minimum PPV of 
46%. This information can help test developers in decisions on further research 
and development.
CN4
THE COST Of COSTING TREATmENTS INCORRECTLy: ERRORS IN THE 
APPLICATION Of dRUG PRICES IN ECONOmIC mOdELS dUE TO dIffERING 
PATIENT wEIGHTS
Hatswell A.J.1, Porter J.1, Hertel N.2, Lee D.1
1BresMed, Sheffield, UK, 2Bristol Myers Squibb, Uxbridge, UK
Objectives: Drug costs are generally a key driver of the results of economic models. 
We tested the impact on drug cost estimates for the following common approaches: 
using mean patient weight, individual patient weights or fitting a distribution to the 
observed patient weights. MethOds: For the analysis, we utilised patient weight 
and height data from trial CA184-024 (517 patients) in metastatic melanoma. Based 
on this dataset, costs of a single administration of drug therapy were calculated 
using UK list prices. Costs were calculated for four recently licensed treatments 
with different posologies: ipilimumab (mg/kg, with 2 vial sizes), cabazitaxel (mg/
m2), ustekinumab (doubled dosage over 100kg patient weight) and romiplostim (µg/
kg, with a large, single vial size). Results: Cost estimates using the mean patient 
weight were £18,750, £3,696, £2,147 and £482 per administration of ipilimumab, 
cabazitaxel, ustekinumab and romiplostim, respectively. These results increased 
by 4.9%, 2.3%, 10.3% and 36.6% when costing individual patient weights, and by 
5.2%, 2.3%, 11.8% and 36.9% when fitting a distribution to the patient weights. The 
use of only mean patient weight consistently underestimated costs compared to 
methods that incorporated the distribution of weight data. Sampling from the 
observed patient weight distribution provides a more accurate estimation of costs; 
however, it is subject to over- or under-estimation, depending on enrolment in 
a trial programme, particularly amongst patients who are substantially over- or 
under-weight. cOnclusiOns: Accurate estimation of drug costs requires an under-
standing of the distribution of patient weights. Failing to take this into account can 
result in cost estimates that are substantially lower than will be seen in practice, 
which could (in turn) impact treatment (implementation) decisions. These errors 
would be further compounded should drug wastage not be adequately captured. 
Modellers should be mindful of these issues when costing therapies or conducting 
health technology assessment submissions.
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validity of network meta-analysis; and (iv) the possibility of disagreement between 
direct evidence and indirect evidence. We illustrate the framework using a network 
meta-analysis of topical antibiotics without steroids for chronically discharging ears 
with underlying eardrum perforations.
CP4
AmENdING THE GUIdE TO mETHOdS Of TECHNOLOGy APPRAISAL AT NICE TO 
INCORPORATE TwO NEw vALUE ELEmENTS: BURdEN Of ILLNESS ANd wIdER 
SOCIETAL ImPACT
Knight H.1, Boysen M.1, Stevens A.2, Longson C.1
1National Institute for Health and Care Excellence, Manchester, UK, 2University of Birmingham, 
Birmingham, UK
bAckgROund: In July 2013 the Department of Health referred terms of refer-
ence for value based assessment of health technologies to NICE. Objective: We 
present the approach taken over the past 11 months to amending the Guide to 
Methods of Technology Appraisal to incorporate burden of illness and wider societal 
impact. MethOds: Given the time frame available, NICE built on prior work under-
taken by the Department of Health (in the context of value based pricing) on the 
concepts of burden of illness and wider societal benefits by commissioning the NICE 
Decision Support Unit to review and critique this existing work. NICE reconvened the 
working party from the Guide to the Methods of Technology Appraisal review which 
took place in 2012, which included standing membership drawn from the stake-
holder communities such as patient and professional organisations, academia and 
pharmaceutical industry. The working party considered the prior work undertaken 
by the Department of Health and the Decision Support Unit’s critique for burden of 
illness and wider societal benefit, and provided advice on the incorporation of the 
2 new value elements into NICE’s current methods at 4 meetings. A consultation 
paper describing NICE’s proposals and draft of the amended sections of the methods 
guide was published in March 2014, and consultation ran for 12 weeks. It is antici-
pated that the final amendment of the methods guide will be considered by the 
NICE Board in advance of the ISPOR conference. Results: Key points drawn from 
the discussion at the working party and consultation responses regarding burden 
of illness and wider societal impact, will be discussed. discussiOn: Considering 
NICE’s ‘position’ in the world of health technology assessment and appraisal, the 
conclusions from this latest amendment of the Guide to Methods of Technology 
Appraisal to incorporate value based assessment will be (highly) anticipated.
dIAGNOSTIC RESEARCH STUdIES
dI1
COST-EffECTIvENESS (CE) Of ImAGING-GUIdEd STRATEGIES fOR THE 
dIAGNOSIS Of CORONARy ARTERy dISEASE (CAd): RESULTS fROm THE EvINCI 
STUdy
Lorenzoni V.1, Pierotti F.1, Bellelli S.1, Neglia D.2, Rovai D.2, Turchetti G.1
1Scuola Superiore Sant’Anna, Pisa, Italy, 2National Research Council, Pisa, Italy
Objectives: To evaluate the cost-effectiveness (CE) of imaging-guided strategies 
for the diagnosis of significant coronary artery disease (CAD) in patients with inter-
mediate pre-test likelihood. MethOds: Significant CAD was defined at invasive 
coronary angiography (ICA) as > 50% stenosis in the left main or > 70% stenosis in 
a major coronary vessel or 30-70% stenosis with fractional flow reserve ≤ 0.8.Nine 
diagnostic strategies were compared using a CE analysis. Strategies included the use 
of one single or two combined non-invasive imaging tests (CTCA as first line test 
and then stress ECHO, CMR, PET or SPECT) followed by ICA in the case of positivity 
of the single test or both non-invasive examinations in the case of combinations. 
ICERs were obtained using per-patient data collected throughout the EVINCI multi-
centre European study. Strategy costs were calculated using examination country-
specific reimbursements, while effectiveness was defined as the percentage of 
correct diagnosis. All costs were converted to Euro 2012 and adjusted using PPP. A 
propensity-score adjustment was used in the analysis and 95%CI were obtained 
with non-parametric bootstrap. Results: Among the strategies analysed only three 
resulted cost-effective for the diagnosis of significant CAD. These included stress 
ECHO and CTCA as single non-invasive test, CTCA first then ECHO, CTCA first and 
then stress PET, all followed by ICA when required. Stress ECHO approach was the 
least costly but also the least effective, while CTCA alone [ICER: 2345 (2287-2400)] or 
in combination with PET [ICER: 5227(5161-5296)] had increasingly higher effective-
ness for a willingness to pay (WTP) exceeding 2,000 Euro and 5,000 Euro, respec-
tively. cOnclusiOns: Results from the health-economic analysis of the EVINCI 
study showed that stress ECHO guided diagnostic strategy could be cost-effective 
when the WTP is low. Strategies involving CTCA alone or as first line exam followed 
by stress PET could allow a more accurate diagnostic workflow for higher WTP.
dI2
THE vALUE Of RISk-STRATIfIEd INfORmATION IN THE NATIONAL LUNG 
CANCER SCREENING TRIAL
Soeteman D.I.1, Cohen J.T.1, Neumann P.J.2, Wong J.B.1, Kent D.M.1
1Tufts Medical Center/Tufts University School of Medicine, Boston, MA, USA, 2Tufts Medical 
Center, Boston, MA, USA
Objectives: Clinical guideline recommendations are generally informed by pop-
ulation-based evidence. However, interventions that are (cost-)effective on average 
may not be (cost-)effective for many (even for most) patients meeting trial inclusion 
criteria. This study aims to investigate the value of risk-stratified recommendations 
for lung cancer screening among current or former smokers between the ages of 
55 and 74 years compared to a screen-all policy. MethOds: Using data from the 
National Lung Cancer Screening Trial (NLST), we calculated the costs and QALYs 
for low-dose computed tomography (CT) versus chest radiography (X-ray) from 
empirically observed health states and 6 years life expectancy. Based on Kovalchik’s 
risk of lung cancer death prediction model, we stratified 53,454 NLST trial patients 
into quintiles. The expected value of individualized care (EVIC) was calculated to 
CONCEPTUAL PAPERS
CP1
THE EvALUATION Of ECONOmIC mETHOdS TO ASSESS THE SOCIAL vALUE Of 
mEdICAL INTERvENTIONS fOR ULTRA-RARE dISORdERS (URdS)
Schlander M.1, Garattini S.2, Holm S.3, Kolominsky-Rabas P.L.4, Nord E.5, Persson U.6,  
Postma M.J.7, Richardson J.8, Simoens S.9, de Sola-Morales O.10, Tolley K.11, Toumi M.12
1Institute for Innovation & Valuation in Health Care (InnoVal-HC), Wiesbaden, Germany, 2Mario 
Negri Institute for Pharmacological Research, Milano, Italy, 3University of Manchester, Manchester, 
UK, 4University of Erlangen, Erlangen, Germany, 5Norwegian Institute of Public Health, Oslo, 
Norway, 6The Swedish Institute for Health Economics (IHE), Lund, Sweden, 7University of 
Groningen, Groningen, The Netherlands, 8Monash University, Clayton, Victoria, Australia, 9KU 
Leuven, Leuven, Belgium, 10Sabirmedical, Barcelona, Spain, 11Tolley Health Economics Ltd., 
Buxton, Derbyshire, UK, 12University Claude Bernard Lyon 1, Lyon, France
Objectives: To develop a set of criteria to critically appraise the strengths and 
weaknesses of health economic methods for the systematic valuation of interven-
tions for ultra-rare disorders (URDs). MethOds: An international group of clinical 
and health economic experts met in conjunction with the Annual European ISPOR 
Congresses in Berlin/Germany and Dublin/Ireland, November 2012 and 2013, to 
deliberate and agree on a set of criteria to assess the potential of the various meth-
ods, which have been used or proposed to estimate the social value of medical 
interventions for URDs. Results: The group identified a broad set of potential 
criteria, which may be grouped according to the following dimensions: theoreti-
cal foundations (normative premises, i.e., links to moral and economic theories, 
including - but not limited to – nonutilitarian consequentialist and deontological 
reasoning, definition and treatment of core concepts of economic thinking such 
as opportunity costs and efficiency), empirical underpinnings (social preferences 
related to attributes of the health condition or of the person afflicted with it), and 
pragmatic aspects (feasibility of implementation and potential for bias and misuse). 
For each of the dimensions, a set of criteria has been agreed upon, which in turn 
will need further scrutiny and justification. cOnclusiOns: Previously, a need had 
been identified for modifications or alternatives to the conventional logic of cost 
effectiveness applying benchmarks for the maximum allowable cost per quality-
adjusted life year (QALY). We propose a framework for the systematic assessment 
how well different evaluation approaches reflect prevalent social norms and value 
judgments. As a next step, the framework shall be applied on multi-criteria decision 
analysis methods and social cost value analysis, either using the person trade-off 
(PTO) or the relative social willingness-to-pay (RS-WTP) instrument.
CP2
vALUE IN THE mAkING: HARvESTING THE vALUE Of COmPLEx mEdICAL 
INNOvATIONS IN PRACTICE
Abrishami P.1, Boer A.2, Horstman K.1
1Maastricht University, Maastricht, The Netherlands, 2National Health Care Institute, Diemen, The 
Netherlands
Rapid development of medical innovations in the face of rising health care costs have 
been calling for a more value-conscious adoption and diffusions of innovations. This 
conceptual paper departs from swift adoption of the da Vinci surgical robot in the 
Netherlands. It describes three challenges facing health care systems to evaluate 
promising, yet complex and often expensive medical innovations. Firstly, they are 
often adopted and diffused prior to their evidence-based superiority being proven. 
Secondly, formal evaluation frameworks are somehow detached from the dynamics 
of and incentives for adoption and diffusion of these innovations. Third, the real risks 
and benefits of these innovations are not easily amenable to an experimental inquiry. 
Unlike pharmaceuticals, whose impact is intrinsic to its biochemical components and 
thus can be subject to experiment, the value of complex surgical devices, imaging 
equipments, or targeted therapy interventions are inseparable from actual patterns 
of human practices and clinical pathways that utilize them. Multi-stakeholder (early) 
deliberation has often been proposed to better align value requirements with the 
adoption and diffusion processes. This article examines the importance of developing 
a shared value perspective on the implementation of complex innovations through 
early deliberation. Product developers, (potential) adopters (providers or patients), 
purchasers, and policy makers may engage in an upfront iterative deliberation on all 
the particularities and (pre)conditions that account for delivering value of a certain 
innovation during early adoption in a given care delivery setting. Such deliberation 
offers a cumulative learning as to how to reduce true-to-life uncertainties and risks 
‘along the way’, thereby serving for value ‘fulfillment’ in practice. Implication of such 
situated deliberative platforms for technology (outcome) assessment and for the role 
of authorities is discussed. A concrete framework for multi-stakeholder deliberation 
applied to the case of the da Vinci surgical robot in the Netherlands is also proposed.
CP3
EvALUATING THE QUALITy Of EvIdENCE fROm A NETwORk mETA-ANALySIS
Higgins J.P.1, Del Giovane C.2, Chaimani A.3, Caldwell D.M.1, Salanti G.3
1University of Bristol, Bristol, UK, 2University of Modena and Reggio Emilia, Modena, Italy, 
3University of Ioannina School of Medicine, Ioannina, Greece
Systematic reviews that collate data about the relative effects of multiple inter-
ventions via network meta-analysis are highly informative for decision-making 
purposes. A network meta-analysis provides two types of findings for a specific 
outcome: the relative treatment effect for all pairwise comparisons, and a rank-
ing of the treatments. It is important to consider the confidence with which these 
two types of results can enable clinicians, policy makers and patients to make 
informed decisions. We propose an approach to determining confidence in the 
output of a network meta-analysis, based on methodology developed by the Grading 
of Recommendations Assessment, Development and Evaluation (GRADE) Working 
Group for pairwise meta-analyses. The suggested framework for evaluating a 
network meta-analysis acknowledges (i) the key role of indirect comparisons (ii) 
the contributions of each piece of direct evidence to the network meta-analysis 
estimates of effect size; (iii) the importance of the transitivity assumption to the 
